Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Trial details
- Registry ID
- NCT07621718
- Phase
- Phase 3
The FDA approved Irinotecan (Camptosar) on 14 Jun 1996.
Drug identity checked against registry records
Also recorded as Camptosar
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )NCT07621718 | RVMD | Phase 3 | Recruiting | 2028-12-30Estimated |
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320 | RVMD | Phase 3 | Active not recruiting | 2026-06Estimated |
| 9-ING-41 in Patients With Advanced CancersNCT03678883 | ACTU | Phase 2 | Active not recruiting | 2026-06Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1996-06-14Day | Irinotecan | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020571", "applicant_as_listed_by_fda": "PFIZER INC", "brand_names": ["CAMPTOSAR"], "active_ingredients": ["IRINOTECAN HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19960614", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |